Diagnosis and evaluation of elderly-onset myasthenia gravis: A case report

Takako Tachikawa,Shinichi Takeshima,Nobuyuki Kawate
DOI: https://doi.org/10.1097/md.0000000000036989
IF: 1.6
2024-02-03
Medicine
Abstract:Myasthenia gravis (MG) is an autoimmune disease characterized by clinical manifestations such as fatigable weakness of ocular, bulbar, respiratory, and limb muscles, brought on by autoantibodies acting on various components of the postsynaptic membrane. [ 1 ] MG patients are classified based on the type of autoantibodies detected in their serum, including antibodies against acetylcholine receptors (AChR), muscle-specific tyrosine kinases, and lipoprotein-related protein 4. [ 1 ] Recently, an increasing number of elderly-onset cases (age of onset >65 or >70 years) have been reported in various countries, [ 2–4 ] including Japan. [ 5 ] The prognosis for patients with elderly-onset MG has been considered poor because of the numerous complications and changes in pharmacokinetics, which limit the application of aggressive treatment strategies. [ 3 ] Lately, however, elderly-onset MG has been shown to be more responsive to treatment than cases with earlier onset <65 years of age [ 6 ] and even low-to-moderate doses of steroids appear to be sufficiently effective. [ 5 ] Thus, the pathogenesis of elderly-onset MG remains unclear. Because of it, it is necessary to diagnose and detect MG exacerbations based on the symptoms and course of the disease in elderly patients to promptly provide them with specialized medical care. About 20% of elderly patients with cerebral small vessel disease, however, have dysphagia, even though they are apparently healthy, [ 7 ] and it is difficult to distinguish in some cases between this and dysphagia caused by MG. In other words, it is not easy to distinguish between an exacerbation of MG symptoms and age-related changes, which can make reaching a diagnosis difficult.
medicine, general & internal
What problem does this paper attempt to address?